Omeros Corporation is a biopharmaceutical company that develops and commercializes small-molecule and protein therapeutics for various diseases, including inflammation, complement-mediated diseases, cancers related to immune system dysfunction, and addictive and compulsive disorders. Its clinical programs include Narsoplimab for various indications, PPAR? for addiction, and PDE7 for addiction and movement disorders. Its preclinical programs include MASP-2 inhibitors for various diseases, CAR T-Cell therapies for cancer, and G protein-coupled receptor targets for various disorders. The company was founded in 1994 and is based in Seattle, Washington.